Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
IPO Year: 2014
Exchange: NASDAQ
Website: adamaspharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2021 | $8.50 | Outperform → Market Perform | Northland Capital Markets |
| 10/12/2021 | Market Outperform → Market Perform | JMP Securities | |
| 10/12/2021 | $7.00 → $8.00 | Overweight → Neutral | Piper Sandler |
| 10/12/2021 | $10.00 → $9.10 | Buy → Neutral | HC Wainwright & Co. |
| 10/11/2021 | Outperform → Market Perform | William Blair |